Ganirelix

Ganirelix is a synthetic decapeptide and a competitive gonadotropin-releasing hormone (GnRH) antagonist. Derived from endogenous GnRH, ganirelix has amino acid substitutions. Ganirelix is indicated in controlled ovarian hyperstimulation in assisted reproduction techniques. The first case of pregnancy achieved after the use of ganirelix in an assisted reproduction program was reported in 1998. Ganirelix was first approved by the FDA on July 29, 1999. It is grouped under the following drug class(es): Hormones, LHRH analogues and Peptides. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Antarelix, Orgalutran and Ganirelixum. Its PubChem CID is 16130957.

CAS No 124904-93-4
Molecular Formula C80H113ClN18O13
Molecular Weight 1570.3 g/mol
Synonyms (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]amino]-4-methylpentanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide

Zoho Contact Form

"*" indicates required fields

I am a*
This field is for validation purposes and should be left unchanged.

Frequently Asked Questions